Accessibility Menu
BioNexus Gene Lab logo

BioNexus Gene Lab

(NASDAQ) BGLC

Current Price$2.22
Market Cap$5.37M
Since IPO (2020)-95%
5 Year-82%
1 Year-39%
1 Month+2%

BioNexus Gene Lab Financials at a Glance

Market Cap

$5.37M

Revenue (TTM)

$5.31M

Net Income (TTM)

-$2.90M

EPS (TTM)

-$1.49

P/E Ratio

-1.49

Dividend

$0.00

Beta (Volatility)

0.39 (Low)

Price

$2.22

Volume

8,282

Open

$2.05

Previous Close

$2.22

Daily Range

$2.05 - $2.42

52-Week Range

$1.92 - $15.60

BGLC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioNexus Gene Lab

Industry

Trading Companies and Distributors

Employees

16

CEO

Su Leng Tan Lee

Headquarters

Kuala Lumpur, 59200, MY

BGLC Financials

Key Financial Metrics (TTM)

Gross Margin

14%

Operating Margin

-55%

Net Income Margin

-55%

Return on Equity

-37%

Return on Capital

-14%

Return on Assets

-14%

Earnings Yield

-67.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.37M

Shares Outstanding

2.42M

Volume

8.28K

Avg. Volume

9.51K

Financials (TTM)

Gross Profit

$1.09M

Operating Income

-$3.16M

EBITDA

-$2.80M

Operating Cash Flow

-$1.84M

Capital Expenditure

-$36.97K

Free Cash Flow

-$1.88M

Cash & ST Invst.

$2.38M

Total Debt

$176.05K

BioNexus Gene Lab Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$22.84K

-98.9%

Gross Profit

-$22.73K

-106.6%

Gross Margin

-99.51%

N/A

Market Cap

$5.37M

N/A

Market Cap/Employee

$178.88K

N/A

Employees

30

N/A

Net Income

-$543.58K

+12.8%

EBITDA

-$527.55K

+3.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$3.75M

+10.4%

Accounts Receivable

$141.47K

-92.0%

Inventory

$667.15K

-43.4%

Long Term Debt

$150.41K

+1.7%

Short Term Debt

$66.02K

+26.5%

Return on Assets

-13.70%

N/A

Return on Invested Capital

-14.30%

N/A

Free Cash Flow

-$148.00K

+82.2%

Operating Cash Flow

-$147.67K

+82.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APMAptorum Group Limited
$0.80-5.96%
MBIOMustang Bio, Inc.
$0.62-2.62%
ADVBAdvanced Biomed Inc. Common Stock
$4.04+4.20%
TRIBTrinity Biotech plc
$0.67-0.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
CZRCaesars Entertainment
$28.78+0.01%
ASTCAstrotech
$13.81+4.59%
SIDUSidus Space
$6.09-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$16.28+0.03%

Questions About BGLC

What is the current price of BioNexus Gene Lab?

BioNexus Gene Lab is trading at $2.22 per share.

What is the 52-week range for BioNexus Gene Lab?

Over the past 52 weeks, BioNexus Gene Lab has traded between $1.92 and $15.60.

How much debt does BioNexus Gene Lab have?

As of the most recent reporting period, BioNexus Gene Lab reported total debt of $216.43K.

How much cash does BioNexus Gene Lab have on hand?

BioNexus Gene Lab reported $3.96M in cash and cash equivalents in its most recent financial results.

What is BioNexus Gene Lab’s dividend yield?

BioNexus Gene Lab does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.